<DOC>
	<DOC>NCT01207011</DOC>
	<brief_summary>The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<criteria>Histological or cytological diagnosis of nonsmall cell lung cancer (NSCLC) 1 or 2 prior chemotherapy regimen including 1 platinumbased chemotherapy 20 or older but younger than 75 years of age Symptomatic brain metastasis Interstitial pneumonia or pulmonary fibrosis Abnormal cardiac function or myocardial infraction within 6 months before study enrollment Active infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>